Surrogate response biomarkers in prevention research: Do they point the way or lead us astray?

Journal of Clinical Oncology

Volumn 27, Issue 23, 2009, Pages 3734-3736

  Fabian, Carol J ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FENRETINIDE; LETROZOLE; PLACEBO; RETINOL BINDING PROTEIN 4; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; TAMOXIFEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; BREAST; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; CYTOLOGY; DENSITY; EDITORIAL; GENE EXPRESSION; HISTOLOGY; HORMONE SUBSTITUTION; HUMAN; INSULIN SENSITIVITY; INTRADUCTAL CARCINOMA; LOW DRUG DOSE; MAMMOGRAPHY; PREMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION; TREATMENT OUTCOME; ADULT; BLOOD; BREAST TUMOR; DISEASE COURSE; FEMALE; LUNG CARCINOMA; METABOLISM; METHODOLOGY; MIDDLE AGED; NOTE; PATHOLOGY; PREDICTION AND FORECASTING; RADIOGRAPHY; TUMOR RECURRENCE;

ADULT; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; DISEASE PROGRESSION; FEMALE; FENRETINIDE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; RESEARCH DESIGN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 68949121023     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.9211     Document Type: Editorial

References (30)

1. Decensi A, Robertson C, Guerrieri-Gonzaga A, et al: Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 27:3749-3756, 2009
2. Guerrieri-Gonzaga A, Robertson C, Bonanni B, et al: Preliminary results on safety and activity of a randomized, double-blind, 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 24:129-135, 2006
3. Schernhammer ES, Holly JM, Pollak MN, et al: Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14:699-704, 2005
4. Pollak MN, Huynh HT, Lefebvre SP: Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Res Treat 22:91-100, 1992
5. Decensi A, Bonanni B, Baglietto L, et al: A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res 10:4389-4397, 2004
6. Santen RJ, Boyd NF, Chlebowski RT, et al: Critical assessment of new risk factors for breast cancer: Considerations for development of an improved risk prediction model. Endocr Relat Cancer 14:169-187, 2007
7. Martin LJ, Boyd NF: Mammographic density: Potential mechanisms of breast cancer risk associated with mammographic density - Hypotheses based on epidemiological evidence. Breast Cancer Res 10:201, 2008
8. Boyd NF, Guo H, Martin LJ, et al: Mammographic density and the risk and detection of breast cancer. N Engl J Med 356:227-236, 2007
9. Fehringer G, Ozcelik H, Knight JA, et al: Association between IGF1 CA microsatellites and mammographic density, anthropometric measures, and circulating IGF-I levels in premenopausal Caucasian women. Breast Cancer Res Treat [epub ahead of print on September 11, 2008]
10. Tamimi RM, Cox DG, Kraft P, et al: Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: A cross-sectional study. Breast Cancer Res 9:R18, 2007
11. Hartmann LC, Sellers TA, Frost MH, et al: Benign breast disease and the risk of breast cancer. N Engl J Med 353:229-237, 2005
12. Fabian CJ, Kimler BF, Zalles CM, et al: Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92:1217-1227, 2000
13. Decensi A, Veronesi U, Miceli R, et al: Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 9:4722-4729, 2003
14. Fabian CJ, Kimler BF: Selective estrogen receptor modulators for primary prevention of breast cancer. J Clin Oncol 23:1644-1655, 2005
15. Wang TT, Phang JM: Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells. Cancer Lett 107:65-71, 1996
16. Ursin G, Astrahan MA, Salane M, et al: The detection of changes in mammographic densities. Cancer Epidemiol Biomarkers Prev 7:43-47, 1998
17. Patel JB, Mehta J, Belosay A, et al: Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer 96:1204-1215, 2007
18. Simeone AM, Li YJ, Broemeling LD, et al: Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells. Cancer Res 64:1224-1228, 2004
19. Yang Q, Graham TE, Mody N, et al: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356-362, 2005
20. Coward P, Conn M, Tang J, et al: Application of an allosteric model to describe the interactions among retinol binding protein 4, transthyretin, and small molecule retinol binding protein 4 ligands. Anal Biochem 384:312-320, 2009
21. Johansson H, Gandini S, Guerrieri-Gonzaga A, et al: Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 68:9512-9518, 2008
22. Andrews WJ, Winnett G, Rehman F, et al: Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production. J Steroid Biochem Mol Biol 94:159-165, 2005
23. Cuzick J, Warwick J, Pinney E, et al: Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 96:621-628, 2004
24. Fabian CJ, Kimler BF: Mammographic density: Use in risk assessment and as a biomarker in prevention trials. J Nutr 136:2705S-2708S, 2006 (suppl)
25. Harper-Wynne C, Ross G, Sacks N, et al: Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: A pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 11:614-621, 2002
26. Fabian CJ, Kimler BF, Zalles CM, et al: Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 106:75-84, 2007
27. Cigler T, Yaffe MJ, Johnston D, et al: A placebo-controlled trial examining the effects of letrozole on mammographic breast density and bone and lipid metabolism. Breast Cancer Res Treat 106:S112, 2007 (suppl 1; abstract 2082)
28. Fabian CJ, Kimler BF, Mayo MS, et al: Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 12:185-213, 2005
29. Fabian CJ, Kimler BF: Use of biomarkers for breast cancer risk assessment and prevention. J Steroid Biochem Mol Biol 106:31-39, 2007
30. Dowsett M, Ebbs SR, Dixon JM, et al: Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists. J Clin Oncol 23:2477-2492, 2005